|Day's Range||0.03 - 0.03|
|52 Week Range||0.02 - 0.08|
|PE Ratio (TTM)||-10.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Med BioGene Inc. today wishes to announce the next phase in its corporate history. After extensive good-faith negotiations, MBI and Helomics Corporation ...
Med BioGene Inc. is very pleased to be able to confirm that our licensee, Helomics has advised us that logistical procedures necessary for the first commercial application of GeneFX Lung will commence ...
Med BioGene Inc. announces that it has granted stock options to directors and senior officers to purchase up to an aggregate of 3,750,000 common shares in the capital of the Company. The options are exercisable ...